Trogocytosis of tumor-derived antigens enables CD8+ T cells to activate other CTLs (Figs. 1 and 2), but may also mark CD8+T-APCs for killing by tumor-reactive CTLs (fratricide) [31]. The gene discussed is CD8A; the disease is neoplasm.